Display options
Share it on

Cancers (Basel). 2021 May 12;13(10). doi: 10.3390/cancers13102344.

Photosensitizing Medications and Skin Cancer: A Comprehensive Review.

Cancers

Elisabeth A George, Navya Baranwal, Jae H Kang, Abrar A Qureshi, Aaron M Drucker, Eunyoung Cho

Affiliations

  1. Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
  2. Channing Division of Network Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115, USA.
  3. Department of Dermatology, Rhode Island Hospital and Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.
  4. Department of Epidemiology, School of Public Health, Brown University, Providence, RI 02903, USA.
  5. Division of Dermatology, Department of Medicine, University of Toronto, Toronto, ON M5S 3H2, Canada.
  6. Women's College Research Institute and Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, ON M5S 1B2, Canada.
  7. Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.

PMID: 34066301 PMCID: PMC8152064 DOI: 10.3390/cancers13102344

Abstract

(1) The incidence of skin cancer is increasing in the United States (US) despite scientific advances in our understanding of skin cancer risk factors and treatments. In vitro and in vivo studies have provided evidence that suggests that certain photosensitizing medications (PSMs) increase skin cancer risk. This review summarizes current epidemiological evidence on the association between common PSMs and skin cancer. (2) A comprehensive literature search was conducted to identify meta-analyses, observational studies and clinical trials that report on skin cancer events in PSM users. The associated risks of keratinocyte carcinoma (squamous cell carcinoma and basal cell carcinoma) and melanoma are summarized, for each PSM. (3) There are extensive reports on antihypertensives and statins relative to other PSMs, with positive and null findings, respectively. Fewer studies have explored amiodarone, metformin, antimicrobials and vemurafenib. No studies report on the individual skin cancer risks in glyburide, naproxen, piroxicam, chlorpromazine, thioridazine and nalidixic acid users. (4) The research gaps in understanding the relationship between PSMs and skin cancer outlined in this review should be prioritized because the US population is aging. Thus the number of patients prescribed PSMs is likely to continue to rise.

Keywords: basal cell carcinoma; melanoma; photosensitizing medication; squamous cell carcinoma

References

  1. Heart Rhythm. 2020 Apr;17(4):560-566 - PubMed
  2. Nat Rev Clin Oncol. 2017 Aug;14(8):463-482 - PubMed
  3. Mol Carcinog. 2018 Aug;57(8):997-1007 - PubMed
  4. Photochem Photobiol Sci. 2018 Dec 5;17(12):1885-1903 - PubMed
  5. Cancer. 2016 Apr 1;122(7):1000-8 - PubMed
  6. J Antimicrob Chemother. 1994 Apr;33(4):685-706 - PubMed
  7. Acta Derm Venereol. 1996 Sep;76(5):337-40 - PubMed
  8. J Phys Chem A. 2008 Oct 30;112(43):10921-30 - PubMed
  9. BMJ. 2006 Dec 16;333(7581):1248 - PubMed
  10. J Natl Cancer Inst. 2019 Dec 1;111(12):1279-1297 - PubMed
  11. Br J Dermatol. 1995 Jul;133(1):148-9 - PubMed
  12. Diabetes Ther. 2012 Dec;3(1):14 - PubMed
  13. Toxicol Sci. 2010 Nov;118(1):236-50 - PubMed
  14. Anticancer Res. 2019 Sep;39(9):4597-4602 - PubMed
  15. Eur J Cancer. 2013 Dec;49(18):3863-71 - PubMed
  16. Case Rep Dermatol. 2017 Oct 20;9(3):211-216 - PubMed
  17. Expert Opin Drug Saf. 2007 Jul;6(4):431-43 - PubMed
  18. Am J Clin Oncol. 2001 Aug;24(4):379-81 - PubMed
  19. Med Oncol. 2007;24(1):1-6 - PubMed
  20. Photodermatol Photoimmunol Photomed. 2000 Jun;16(3):116-20 - PubMed
  21. Apoptosis. 2018 Oct;23(9-10):532-553 - PubMed
  22. Chem Biol Interact. 2019 Apr 25;303:27-34 - PubMed
  23. Dermatol Ther. 2019 Jan;32(1):e12748 - PubMed
  24. Dermatol Surg. 2020 Sep;46(9):1135-1140 - PubMed
  25. Pharmacol Res. 2020 Feb;152:104499 - PubMed
  26. J Hypertens. 2019 Oct;37(10):1950-1958 - PubMed
  27. Melanoma Res. 2003 Feb;13(1):87-91 - PubMed
  28. Neoplasia. 2007 Dec;9(12):1078-90 - PubMed
  29. Int J Radiat Oncol Biol Phys. 1992;22(1):224 - PubMed
  30. BMJ Open. 2016 Mar 24;6(3):e010989 - PubMed
  31. Br J Dermatol. 2014 Apr;170(4):930-8 - PubMed
  32. J Invest Dermatol. 2013 Aug;133(8):1950-5 - PubMed
  33. J Dermatol Sci. 2016 Dec;84(3):330-339 - PubMed
  34. Drug Saf. 2019 Jul;42(7):827-847 - PubMed
  35. J Control Release. 2010 Dec 20;148(3):303-10 - PubMed
  36. Expert Opin Drug Saf. 2014 Jan;13(1):57-65 - PubMed
  37. Clin Transplant. 2016 Nov;30(11):1377-1386 - PubMed
  38. Arch Toxicol. 2012 Mar;86(3):483-96 - PubMed
  39. Br J Cancer. 2008 Nov 4;99(9):1522-8 - PubMed
  40. J Am Acad Dermatol. 2019 Feb;80(2):500-507.e10 - PubMed
  41. Antimicrob Agents Chemother. 1993 Oct;37(10):2217-23 - PubMed
  42. Cancer. 2013 May 1;119(9):1699-705 - PubMed
  43. JAMA Dermatol. 2019 Mar 1;155(3):353-357 - PubMed
  44. CMAJ. 2011 Oct 4;183(14):E1073-84 - PubMed
  45. Eur J Clin Pharmacol. 2013 Jul;69(7):1437-44 - PubMed
  46. Br J Dermatol. 2017 Mar;176(3):816-820 - PubMed
  47. CA Cancer J Clin. 2020 Jan;70(1):7-30 - PubMed
  48. Oncotarget. 2017 Aug 8;8(43):75411-75417 - PubMed
  49. Oncogene. 2013 May 23;32(21):2682-9 - PubMed
  50. Arch Pathol Lab Med. 2004 Jul;128(7):807-10 - PubMed
  51. Cancer Prev Res (Phila). 2014 Jan;7(1):54-64 - PubMed
  52. J Eur Acad Dermatol Venereol. 2020 Mar;34(3):589-600 - PubMed
  53. J Invest Dermatol. 1989 Aug;93(2):201-9 - PubMed
  54. J Clin Med Res. 2019 Apr;11(4):247-255 - PubMed
  55. Curr Cardiol Rep. 2019 Jul 27;21(9):92 - PubMed
  56. Cancer Epidemiol Biomarkers Prev. 2011 Oct;20(10):2273-9 - PubMed
  57. Case Rep Dermatol. 2016 Oct 4;8(3):254-261 - PubMed
  58. Br J Cancer. 2014 Feb 4;110(3):802-7 - PubMed
  59. Curr Med Res Opin. 2019 Oct;35(10):1785-1792 - PubMed
  60. Exp Dermatol. 2020 Jan;29(1):29-38 - PubMed
  61. N Engl J Med. 2011 Jun 30;364(26):2507-16 - PubMed
  62. J Renin Angiotensin Aldosterone Syst. 2015 Jun;16(2):227-33 - PubMed
  63. Cochrane Database Syst Rev. 2005 Oct 19;(4):CD003697 - PubMed
  64. J Hypertens. 1990 Jun;8(6):565-72 - PubMed
  65. Crit Rev Oncol Hematol. 2005 Oct;56(1):127-36 - PubMed
  66. Expert Opin Drug Discov. 2016 Sep;11(9):907-16 - PubMed
  67. Drug Deliv. 2019 Dec;26(1):376-383 - PubMed
  68. Clin Exp Dermatol. 2019 Apr;44(3):243-251 - PubMed
  69. Crit Rev Oncol Hematol. 2018 Feb;122:1-9 - PubMed
  70. Nature. 2002 Jun 27;417(6892):949-54 - PubMed
  71. Br J Cancer. 2019 Nov;121(11):973-978 - PubMed
  72. Cancer Epidemiol Biomarkers Prev. 2010 Nov;19(11):2942-9 - PubMed
  73. J Photochem Photobiol B. 2015 Jul;148:168-173 - PubMed
  74. Br J Dermatol. 2004 Oct;151(4):932-3; author reply 933 - PubMed
  75. Photochem Photobiol Sci. 2013 May;12(5):911-22 - PubMed
  76. J Pediatr. 2019 Aug;211:152-158 - PubMed
  77. Br J Cancer. 2018 Jan;118(2):294-298 - PubMed
  78. Turk Kardiyol Dern Ars. 2017 Apr;45(3):268-270 - PubMed
  79. Cancers (Basel). 2020 Apr 28;12(5): - PubMed
  80. Clin Transplant. 2019 Dec;33(12):e13718 - PubMed
  81. Photochem Photobiol. 2010 Jan-Feb;86(1):146-52 - PubMed
  82. J Pharm Biomed Anal. 2020 Aug 5;187:113326 - PubMed
  83. Contact Dermatitis. 1995 Oct;33(4):274 - PubMed
  84. Cell Death Dis. 2011 Sep 01;2:e199 - PubMed
  85. Eur J Epidemiol. 2010;25(1):29-35 - PubMed
  86. Sci Rep. 2018 Mar 22;8(1):5050 - PubMed
  87. Apoptosis. 2011 Dec;16(12):1268-84 - PubMed
  88. Am J Clin Dermatol. 2010;11(1):45-50 - PubMed
  89. Cancer Prev Res (Phila). 2015 Jan;8(1):27-36 - PubMed
  90. Ther Clin Risk Manag. 2019 Sep 12;15:1111-1119 - PubMed
  91. Drug Des Devel Ther. 2015 Oct 29;9:5843-50 - PubMed
  92. Clin Infect Dis. 2014 Apr;58(7):997-1002 - PubMed
  93. Lancet Oncol. 2014 Apr;15(4):436-44 - PubMed
  94. Antimicrob Agents Chemother. 1998 Dec;42(12):3141-5 - PubMed
  95. Drug Saf. 2002;25(5):345-72 - PubMed
  96. Cancer Prev Res (Phila). 2017 Oct;10(10):598-606 - PubMed
  97. Curr Med Res Opin. 2017 Jul;33(7):1255-1259 - PubMed
  98. J Am Acad Dermatol. 2018 Apr;78(4):682-693 - PubMed
  99. G Ital Dermatol Venereol. 2020 Sep 17;: - PubMed
  100. J Natl Cancer Inst. 2006 Nov 1;98(21):1538-46 - PubMed
  101. J Neuroimmune Pharmacol. 2020 Mar;15(1):17-26 - PubMed
  102. Drug Saf. 2015 Oct;38(10):889-94 - PubMed
  103. Cancer Med. 2019 Dec;8(17):7265-7277 - PubMed
  104. Pigment Cell Melanoma Res. 2013 Nov;26(6):874-85 - PubMed
  105. Photochem Photobiol. 2017 Jul;93(4):1016-1024 - PubMed
  106. MMWR Morb Mortal Wkly Rep. 2015 Jun 5;64(21):591-6 - PubMed
  107. Photodermatol Photoimmunol Photomed. 2014 Feb;30(1):8-14 - PubMed
  108. J Photochem Photobiol B. 1989 Apr;3(2):223-35 - PubMed
  109. Eur J Cancer. 2008 Oct;44(15):2122-32 - PubMed
  110. Pharmacoepidemiol Drug Saf. 2018 Mar;27(3):279-288 - PubMed
  111. Arch Dermatol. 2010 Mar;146(3):300-4 - PubMed
  112. Cancer Prev Res (Phila). 2013 Jul;6(7):675-85 - PubMed
  113. JAMA Oncol. 2018 Feb 8;4(2):e172908 - PubMed
  114. Drug Saf. 2018 Feb;41(2):161-169 - PubMed
  115. Pigment Cell Melanoma Res. 2017 May;30(3):378-380 - PubMed
  116. Br J Dermatol. 2018 Nov;179(5):1088-1094 - PubMed
  117. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(5):484-93 - PubMed
  118. Photochem Photobiol. 1996 Apr;63(4):455-62 - PubMed
  119. J Skin Cancer. 2019 Mar 10;2019:7089482 - PubMed
  120. Sci Rep. 2017 Aug 15;7(1):8273 - PubMed
  121. Br J Dermatol. 2015 Sep;173(3):751-9 - PubMed
  122. Arch Dermatol. 2006 Aug;142(8):1082-4 - PubMed
  123. Oncogene. 2019 Mar;38(13):2320-2336 - PubMed
  124. Clin Cosmet Investig Dermatol. 2018 Oct 12;11:485-490 - PubMed
  125. Photodermatol Photoimmunol Photomed. 1994 Dec;10(6):255-8 - PubMed
  126. Int J Clin Pract. 2006 Sep;60(9):1028-34 - PubMed
  127. Int J Dermatol. 2009 Dec;48(12):1398-400 - PubMed
  128. Mayo Clin Proc. 2013 Nov;88(11):1196-203 - PubMed
  129. Int J Cardiol. 2009 Jun 12;135(1):128-30 - PubMed
  130. Br J Dermatol. 1990 Jul;123(1):9-20 - PubMed
  131. Cancer Prev Res (Phila). 2021 Jan;14(1):77-84 - PubMed

Publication Types